December 2021 - Global Life Science Business Partnering - News & Updates


Highlights of December 2021

  1. Piramal Pharma invests Rs 101.77 Cr in CDMO Yapan Bio.
  2. Glenmark's subsidiary Ichnos Sciences inks agreement with Almirall.
  3. Kedaara acquires majority stake in GAVS Technologies.
  4. Aragen Life Sciences acquires Pune-based CRO Intox.
  5. Alembic Pharma announces seed round investment in RIGImmune.
  6. Biocon enters into an out-licensing deal with Tabuk Pharmaceuticals.
  7. Lupin acquires exclusive rights to develop, manufacture TTP inhalation products.
  8. Sun Pharma Advanced Research Company (SPARC) has entered into an agreement with Visiox Pharma (Visiox) to grant exclusive worldwide rights (except for India and Greater China) for the development and commercialization of PDP-716 and SDN-037.
  9. SPARC inks agreement with Biomodifying for cancer research.
  10. Lupin has entered into an exclusive distribution and marketing agreement with Biomm in Brazil. Under the terms of the agreement, Biomm will distribute and market biosimilar Pegfilgrastim in Brazil.
  11. Karyopharm inks commercialization deal for Nexpovio with Menarini.
  12. Nykode and Regeneron in vaccines deal worth potential $925 million.
  13. Novartis inks US$800 Million upfront buyout of Gyroscope to continue eye disease gene therapy M&A spree.
  14. Novo Nordisk to acquire Dicerna Pharmaceuticals.
  15. Hyphens Pharma inks exclusive licensing deal for ustekinumab biosimilar.

Highlights at Aagami:

  1. Aagami gets a licensing term sheet signed for its client. Other details confidential until public press release by the respective parties (both companies are publicly listed).
  2. New Assignment for multiple assets and geographies from Existing Japanese client (Pharma and MedTech).
  3. Meet Aagami CEO Dinesh Jain during JPM and BIOTECH SHOWCASE 2022.
    1. January 10-19, 2022 (Virtually)
    2. Meeting calendar almost filled. Few time options remaining.

INFOCUS: Select opportunities available at Aagami:

 

For Acquisition:

  1. Mountain View Pharma (MVP) including its PharmaPEG® technology, product candidates, data package, & IP - for Next-generation biologics and substantial returns.

 

For Investment/Partnering/Licensing:

  1. US FDA approved portable MRI Guided Treatment, Diagnosis and Screening (Series C Open), limited period offer available for extended Series B.
  2. Series A - $25M Financing: Midwest US based Pharma’s First-in-Class Non-Opioid Analgesic for both chronic and acute Pain Relief – Seeking funding and licensing partnerships.
  3. Licensing, Co-development - Oncology assets such as Docetaxel, Cabazitaxel and Bendamustine, with low cost and accelerated route to market approval (From US subsidiary of a China HQ’d company). Negligible competition(2) for Bendamustine in the $600M US market.
  4. Seeking Licensing/Strategic partnerships our French client’s Phase 2 injectable drug candidate (NFL-101) for smoking cessation. It is delivered subcutaneously, twice, one week apart.
  5. Available for licensing: Phase I asset for Moderate-Severe Pain; Fast Track designation; Clinical Study on-going.
  6. Available for licensing: Transdermal smart patch asset with Proprietary technology for Alzheimer’s Disease; IND filing in progress. Safer and non-irritable.
  7. Technology Licensing: Microneedle Array Patch (MAP) system for drugs, vaccines; better immune response than injection.
  8. Seeking $200,000 in Pre-Seed Bridge Round – Natural and Soluble Melanin (100sX lower cost) with applications in Drugs, Biomedical, cosmetics, Aerospace, energy systems to name a few. Raised $400,000 till date from Indiebio Accelerator, SOSV and other VC funds.
×
Twitter